Emergent BioSolutions secured a new $150 million term loan from OrbiMed to repay its previous loan and amended its asset-based loan facility with Wells Fargo, increasing borrowing capacity to $50 million. Both loans now mature in April 2031, extending previous deadlines by nearly two years. This refinancing reduces interest expenses by 200 basis points annually and offers greater financial flexibility with fewer restrictions, supporting Emergent's multi-year transformation plan and long-term growth. The company aims to strengthen its balance sheet and deploy capital strategically for future opportunities.
The global automotive microcontrollers market is projected to grow from USD 15.49 billion in 2025 to USD 34.31 billion by 2035, at a CAGR of 8.28%. Growth is fueled by increasing adoption of advanced driver-assistance systems (ADAS), vehicle electrif...
B&M European Value Retail's first-quarter update has divided analysts, with Deutsche Bank upgrading the stock to 'hold' citing stabilizing profit margins and a sensible turnaround strategy by new CEO Tjeerd Jegen. Deutsche Bank raised its profit fore...
AmpliTech Group marked its fifth anniversary as a public company by ringing the Nasdaq opening bell and announcing record revenue of $25.2 million in fiscal 2025, a 165% increase year-over-year. The company, a US-based leader in RF and microwave sign...
Telo Genomics announced positive interim results from a clinical study analyzing blood samples of multiple myeloma patients to predict relapse risk using 3D telomere analysis. The test showed strong predictive accuracy, potentially offering a less in...
Meta now notifies parents if their teen talks about suicide or self-harm with its AI chatbot and is developing a feature to contact emergency services if risk is detected. This move addresses concerns about AI chatbots handling crisis conversations, ...
